Le Lézard
Classified in: Health, Business
Subject: VEN

DWHP Invests in CEFALY Technology SPRL


TORONTO, Aug. 8, 2019 /PRNewswire/ -- DW Healthcare Partners ("DWHP"), a healthcare-focused private equity firm, announced today a majority investment in CEFALY Technology SPRL ("CEFALY"), a leading global manufacturer and marketer of neuro-modulating medical devices for the prevention and treatment of migraines. CEFALY is the first investment in DW Healthcare Partners V, L.P., the firm's recently closed, $610 million fifth fund.

DW Healthcare Partners Logo

CEFALY was founded in 2004 by Dr. Pierre Rigaux and Pierre-Yves Muller and is headquartered in Liège, Belgium, with additional operations in the US. The CEFALY device is externally applied by the patient to the forehead to deliver electrical impulses to the trigeminal nerve, a critical component of the nervous system involved in almost all migraines. The device is the only one of its kind registered with the FDA, CE mark certified, and with many years of active commercial use. The company's strong and robust clinical data has established CEFALY as a highly effective and safe solution to alleviate and prevent acute migraine pain.

"DW Healthcare Partners is the ideal partner for CEFALY as the company enters its next stage of rapid growth and continues transforming the way migraines are treated globally," said founder, Dr. Pierre Rigaux.

Gabe Becher, Principal at DWHP stated, "Migraines are unfortunately an extremely prevalent and difficult to treat neurological disease. We are very excited to invest in CEFALY, a business whose highly effective device offers a non-drug solution that significantly improves a migraineur's quality of life."

Concurrent with the closing, DWHP is very pleased to announce the hiring of Jen Trainor as CEFALY's Chief Executive Officer. Jen is a highly accomplished executive with domestic and international experience in marketing, sales, operations and multichannel product distribution. Most recently, Jen was President of a leading, global health and wellness brand at The Nature's Bounty Company.

About DW Healthcare Partners

DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm manages over $1.4 billion in committed capital and invests in leading healthcare companies with proven management teams. DW Healthcare Partners is led by seasoned healthcare executives with more than 120 years of combined industry experience. The firm provides the capital, strategic guidance, and acquisition expertise to help mid-stage companies realize their growth potential. For more information, please visit: www.dwhp.com.

SOURCE DW Healthcare Partners


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: